HER2-directed therapies have transformed the treatment landscape of breast and gastric cancers, but targeting HER2 alterations in non-small cell lung cancer (NSCLC) has proven more challenging. HER2 mutations, found in 2-4% of NSCLC cases, define a unique molecular subset characterized by poor responses to conventional...
Oscar Arrieta, E. Caballé-Pérez, L. Cabrera-Miranda et al.· Critical reviews in oncology...· 0 citations
Cancer genomics and precision oncology are increasingly central to cancer care, but many health systems struggle to implement them equitably, effectively, and sustainably. This Commission defines the current global precision oncology landscape and analyses the scientific, structural, and health-system challenges shapin...
R. Casolino, J. Mateo, E. D. de Vries et al.· The Lancet Oncology· 11 citations
By 2030, an estimated 75% of cancer deaths will occur in low- and middle-income countries (LMICs). Weak surveillance systems and limited research infrastructure often hide the true magnitude of this burden. Thus, independent, locally led research is essential for generating high-quality data, addressing regional diseas...
O. Arrieta, E. Rios-Garcia, Cittim B. Palomares-Palomares et al.· The Oncologist· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
